Experienced in Pacemaker Implantation

Dr. Michael A. Morse

Interventional Cardiology | Cardiology
Saint Thomas Medical Partners
300 20th Ave N, 
Nashville, TN 
Accepting New Patients
Offers Telehealth
Experienced in Pacemaker Implantation
Saint Thomas Medical Partners
300 20th Ave N, 
Nashville, TN 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Michael Morse is an Interventional Cardiologist and a Cardiologist in Nashville, Tennessee. Dr. Morse is rated as an Experienced provider by MediFind in Pacemaker Implantation. His top areas of expertise are Mitral Valve Regurgitation, Aortic Valve Stenosis, Necrosis, Transcatheter Aortic Valve Replacement (TAVR), and Heart Valve Repair. Dr. Morse is currently accepting new patients.

His clinical research consists of co-authoring 241 peer reviewed articles and participating in 10 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Interventional Cardiology
Cardiology
Licenses
Internal Medicine in IL
Hospital Affiliations
Tennova Healthcare-Clarksville
Saint Thomas River Park Hospital
Ascension Saint Thomas Hospital
Williamson Medical Center
West Tennessee Healthcare Henry County Hospital
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Farm Bureau Health Plans
  • HMO
  • MEDICARE MAPD
  • MEDICARE PDP
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
US Health and Life
  • EPO
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 7 Less Insurance Carriers -

Locations

SAINT THOMAS MEDICAL PARTNERS
300 20th Ave N, Nashville, TN 37203
Other Locations
SAINT THOMAS MEDICAL PARTNERS
100 Physicians Way, Suite 330, Lebanon, TN 37090
SAINT THOMAS MEDICAL PARTNERS
4230 Harding Pike, Suite 535, Nashville, TN 37205
SAINT THOMAS MEDICAL PARTNERS
2000 Church St, Nashville, TN 37236

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

10 Clinical Trials

WATCHMAN FLX Versus NOAC for Embolic ProtectION in in the Management of Patients With Non-Valvular Atrial Fibrillation
WATCHMAN FLX Versus NOAC for Embolic ProtectION in in the Management of Patients With Non-Valvular Atrial Fibrillation
Enrollment Status: Active_not_recruiting
Publish Date: December 15, 2025
Intervention Type: Drug, Device
Study Phase: Not Applicable
ACURATE IDE: Transcatheter Replacement of Stenotic Aortic Valve Through Implantation of ACURATE in Subjects InDicatEd for TAVR
ACURATE IDE: Transcatheter Replacement of Stenotic Aortic Valve Through Implantation of ACURATE in Subjects InDicatEd for TAVR
Enrollment Status: Active_not_recruiting
Publish Date: December 10, 2025
Intervention Type: Device
Study Phase: Not Applicable
A Phase I/II Study of Active Immunotherapy With Ad5 [E1-,E2b-]-CEA(6D) Vaccine in Patients With Advanced or Metastatic Malignancies Expressing CEA
A Phase I/II Study of Active Immunotherapy With Ad5 [E1-,E2b-]-CEA(6D) Vaccine in Patients With Advanced or Metastatic Malignancies Expressing CEA
Enrollment Status: Completed
Publish Date: November 25, 2025
Intervention Type: Biological
Study Phase: Phase 1/Phase 2
Edwards EVOQUE Transcatheter Tricuspid Valve Replacement: Pivotal Clinical Investigation of Safety and Clinical Efficacy Using a Novel Device
Edwards EVOQUE Transcatheter Tricuspid Valve Replacement: Pivotal Clinical Investigation of Safety and Clinical Efficacy Using a Novel Device
Enrollment Status: Active_not_recruiting
Publish Date: October 09, 2025
Intervention Type: Device, Drug
Study Phase: Not Applicable
A Multicenter Phase I/II Randomized Phase II Study of Gemcitabine and Nab-Paclitaxel With or Without NPC-1C in Patients With Metastatic or Locally Advanced Pancreatic Cancer Previously Treated With FOLFIRINOX
A Multicenter Phase I/II Randomized Phase II Study of Gemcitabine and Nab-Paclitaxel With or Without NPC-1C in Patients With Metastatic or Locally Advanced Pancreatic Cancer Previously Treated With FOLFIRINOX
Enrollment Status: Terminated
Publish Date: May 07, 2025
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
An Open-Label, Multicenter, Non-Randomized, Dose-Confirmation and Cohort-Expansion Phase 1b Study to Evaluate the Safety, Tolerability, and Anti-Tumor Activity of ATP128, VSV-GP128 and BI 754091, in Patients With Stage IV Colorectal Cancer
An Open-Label, Multicenter, Non-Randomized, Dose-Confirmation and Cohort-Expansion Phase 1b Study to Evaluate the Safety, Tolerability, and Anti-Tumor Activity of ATP128, VSV-GP128 and BI 754091, in Patients With Stage IV Colorectal Cancer
Enrollment Status: Active_not_recruiting
Publish Date: January 29, 2025
Intervention Type: Drug
Study Drugs: ATP-128, BI-754091
Study Phase: Phase 1
Dose Escalation and Expansion Clinical Study to Evaluate the Safety and Efficacy of ELU001 in Subjects Who Have Advanced, Recurrent or Refractory FRα Overexpressing Tumors
Dose Escalation and Expansion Clinical Study to Evaluate the Safety and Efficacy of ELU001 in Subjects Who Have Advanced, Recurrent or Refractory FRα Overexpressing Tumors
Enrollment Status: Terminated
Publish Date: August 07, 2024
Intervention Type: Drug
Study Drug: ELU001
Study Phase: Phase 1/Phase 2
A Phase 1B, Randomized, Open-Label Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) in Combination With Cisplatin Plus Gemcitabine and PEGPH20 in Combination With Atezolizumab and Cisplatin Plus Gemcitabine Compared With Cisplatin Plus Gemcitabine in Subjects With Previously Untreated, Unresectable, Locally Advanced, or Metastatic Intrahepatic and Extrahepatic Cholangiocarcinoma and Gallbladder Adenocarcinoma
A Phase 1B, Randomized, Open-Label Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) in Combination With Cisplatin Plus Gemcitabine and PEGPH20 in Combination With Atezolizumab and Cisplatin Plus Gemcitabine Compared With Cisplatin Plus Gemcitabine in Subjects With Previously Untreated, Unresectable, Locally Advanced, or Metastatic Intrahepatic and Extrahepatic Cholangiocarcinoma and Gallbladder Adenocarcinoma
Enrollment Status: Terminated
Publish Date: February 07, 2020
Intervention Type: Drug
Study Phase: Phase 1
Proleukin Observational Registry to Evaluate the Treatment Patterns and Clinical Response in Malignancy
Proleukin Observational Registry to Evaluate the Treatment Patterns and Clinical Response in Malignancy
Enrollment Status: Completed
Publish Date: June 13, 2019
Percutaneous Ventricular Restoration in Chronic Heart Failure Due to Ischemic Heart Disease
Percutaneous Ventricular Restoration in Chronic Heart Failure Due to Ischemic Heart Disease
Enrollment Status: Terminated
Publish Date: June 23, 2017
Intervention Type: Device
Study Phase: Phase 3
View 9 Less Clinical Trials

241 Total Publications

Percutaneous transcatheter valve replacement in individuals with mitral regurgitation unsuitable for surgery or transcatheter edge-to-edge repair: a prospective, multicountry, single-arm trial.
Percutaneous transcatheter valve replacement in individuals with mitral regurgitation unsuitable for surgery or transcatheter edge-to-edge repair: a prospective, multicountry, single-arm trial.
Journal: Lancet (London, England)
Published: September 15, 2025
Similar Doctors
Advanced in Pacemaker Implantation
Dr. Stephen Fahrig
Cardiology
Advanced in Pacemaker Implantation
Dr. Stephen Fahrig
Cardiology

Ascension Saint Thomas Heart West

4230 Harding Pike Ste 330, 
Nashville, TN 
 (4.8 miles away)
615-269-4545
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Stephen Fahrig is a Cardiologist in Nashville, Tennessee. Dr. Fahrig is rated as a Distinguished provider by MediFind in Pacemaker Implantation. His top areas of expertise are Arrhythmias, Atrial Fibrillation, Atrioventricular Nodal Reentrant Tachycardia (AVNRT), Pacemaker Implantation, and Cardiac Ablation.

Advanced in Pacemaker Implantation
Dr. Gregory G. Bashian
Cardiac Electrophysiology | Cardiology
Advanced in Pacemaker Implantation
Dr. Gregory G. Bashian
Cardiac Electrophysiology | Cardiology

Centennial Heart LLC

2300 Patterson St, 
Nashville, TN 
 (0.4 miles away)
615-222-2100
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Gregory Bashian is a Cardiac Electrophysiologist and a Cardiologist in Nashville, Tennessee. Dr. Bashian is rated as a Distinguished provider by MediFind in Pacemaker Implantation. His top areas of expertise are Atrial Fibrillation, Arrhythmias, Bidirectional Tachycardia, Pacemaker Implantation, and Cardiac Ablation. Dr. Bashian is currently accepting new patients.

Advanced in Pacemaker Implantation
Dr. Przemyslaw P. Borek
Cardiac Electrophysiology | Cardiology
Advanced in Pacemaker Implantation
Dr. Przemyslaw P. Borek
Cardiac Electrophysiology | Cardiology

Centennial Heart LLC

300 Steam Plant Rd, Suite 270, 
Gallatin, TN 
 (26.2 miles away)
615-230-6435
Languages Spoken:
English, Polish
See accepted insurances
Accepting New Patients
Offers Telehealth

Przemyslaw Borek is a Cardiac Electrophysiologist and a Cardiologist in Gallatin, Tennessee. Dr. Borek is rated as a Distinguished provider by MediFind in Pacemaker Implantation. His top areas of expertise are Atrial Fibrillation, Arrhythmias, Catecholaminergic Polymorphic Ventricular Tachycardia, Pacemaker Implantation, and Cardiac Ablation. Dr. Borek is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Morse's expertise for a condition
ConditionClose
    View All 10 Distinguished Conditions
    View All 15 Advanced Conditions
    View All 29 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile